Maurizio D'Incalci Selected Research

delanzomib

1/2013	A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma.
11/2010	Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the determination of the novel proteasome inhibitor CEP-18770 in human plasma and its application in a clinical pharmacokinetic study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Maurizio D'Incalci Research Topics

Disease

105	Neoplasms (Cancer) 02/2024 - 01/2002
29	Ovarian Neoplasms (Ovarian Cancer) 12/2023 - 04/2004
17	Sarcoma (Soft Tissue Sarcoma) 11/2020 - 12/2002
15	Myxoid Liposarcoma 01/2022 - 07/2007
12	Carcinoma (Carcinomatosis) 01/2017 - 04/2002
11	Ovarian Epithelial Carcinoma 01/2023 - 01/2012
8	Breast Neoplasms (Breast Cancer) 01/2022 - 11/2003
7	Malignant Mesothelioma 01/2023 - 01/2017
6	Melanoma (Melanoma, Malignant) 01/2019 - 03/2003
6	Liposarcoma 01/2019 - 07/2007
5	Inflammation (Inflammations) 01/2023 - 04/2005
5	Disease Progression 01/2022 - 03/2016
5	Neoplasm Metastasis (Metastasis) 01/2020 - 08/2003
4	Mesothelioma 01/2023 - 01/2015
4	Colonic Neoplasms (Colon Cancer) 08/2020 - 02/2009
4	Multiple Myeloma 01/2019 - 04/2010
4	Colorectal Neoplasms (Colorectal Cancer) 01/2018 - 07/2012
4	Triple Negative Breast Neoplasms 01/2017 - 02/2013
4	Ewing Sarcoma (Sarcoma, Ewing) 11/2016 - 12/2002
4	Neuroblastoma 08/2012 - 10/2005
3	Neutropenia 11/2020 - 03/2005
3	Leiomyosarcoma 01/2018 - 07/2010
3	Chromosome Aberrations (Chromosome Abnormalities) 09/2009 - 12/2005
2	Fibrosarcoma 11/2021 - 08/2003
2	Glioblastoma (Glioblastoma Multiforme) 05/2019 - 10/2013
2	Adenocarcinoma 01/2018 - 03/2016
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 08/2017 - 12/2016
2	Seizures (Absence Seizure) 03/2017 - 07/2002
2	Epilepsy (Aura) 03/2017 - 07/2002
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 09/2011 - 02/2008
2	Rhabdomyosarcoma 09/2010 - 09/2005

Drug/Important Bio-Agent (IBA)

57	TrabectedinIBA 02/2024 - 01/2002
15	PlatinumIBA 01/2022 - 03/2005
14	Antineoplastic Agents (Antineoplastics)IBA 01/2022 - 04/2002
12	Proteins (Proteins, Gene)FDA Link 01/2023 - 02/2003
11	Biomarkers (Surrogate Marker)IBA 05/2022 - 07/2006
10	MicroRNAs (MicroRNA)IBA 01/2023 - 07/2012
10	Paclitaxel (Taxol)FDA LinkGeneric 09/2021 - 09/2006
9	DNA (Deoxyribonucleic Acid)IBA 12/2023 - 04/2004
8	Cisplatin (Platino)FDA LinkGeneric 07/2019 - 12/2002
7	PM 01183IBA 02/2024 - 11/2013
7	CytokinesIBA 01/2023 - 04/2005
5	ChemokinesIBA 01/2023 - 03/2010
5	Irinotecan (Camptosar)FDA LinkGeneric 11/2016 - 09/2005
4	Imatinib Mesylate (Gleevec)FDA Link 11/2017 - 05/2002
4	Gemcitabine FDA Link 01/2017 - 02/2008
4	Doxorubicin (Adriamycin)FDA LinkGeneric 12/2016 - 08/2003
4	liposomal doxorubicin (Doxil)FDA Link 11/2016 - 08/2010
4	Telomerase (Telomerase Reverse Transcriptase)IBA 12/2005 - 03/2003
3	Messenger RNA (mRNA)IBA 01/2023 - 07/2002
3	Circulating Tumor DNAIBA 07/2022 - 01/2018
3	Pioglitazone (Actos)FDA Link 01/2022 - 12/2019
3	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2022 - 08/2013
3	olaparibIBA 01/2022 - 10/2018
3	Bevacizumab (Avastin)FDA Link 01/2021 - 01/2016
3	AnthracyclinesIBA 11/2020 - 12/2011
3	Interleukin-6 (Interleukin 6)IBA 08/2020 - 04/2005
3	RNA (Ribonucleic Acid)IBA 11/2018 - 01/2012
3	Asparaginase (Elspar)FDA Link 04/2018 - 01/2006
3	Tyrosine Kinase InhibitorsIBA 11/2017 - 02/2013
3	OTX015IBA 01/2017 - 12/2016
3	Ifosfamide FDA LinkGeneric 11/2016 - 12/2011
3	LigandsIBA 11/2015 - 11/2008
3	plitidepsin (aplidine)IBA 01/2014 - 02/2004
3	E-3810IBA 02/2013 - 02/2011
3	3- (4'- hydroxy- 3'- adamantylbiphenyl- 4- yl)acrylic acidIBA 08/2012 - 03/2007
3	RetinoidsIBA 08/2012 - 03/2007
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2011 - 11/2009
3	ST 1481 (Gimatecan)IBA 09/2010 - 10/2005
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2023 - 04/2005
2	AsbestosIBA 01/2023 - 11/2020
2	AlkaloidsIBA 01/2022 - 03/2005
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2021 - 09/2003
2	Alanine Transaminase (SGPT)IBA 01/2021 - 10/2018
2	Carboplatin (JM8)FDA LinkGeneric 01/2021 - 10/2019
2	Transaminases (Aminotransferases)IBA 11/2020 - 03/2005
2	Macrophage Colony-Stimulating FactorIBA 08/2020 - 04/2005
2	Tissue Inhibitor of Metalloproteinase-1IBA 01/2019 - 02/2015
2	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 10/2018 - 08/2013
2	Carbamazepine (Tegretol)FDA LinkGeneric 03/2017 - 07/2002
2	Anticonvulsants (Antiepileptic Drugs)IBA 03/2017 - 07/2002
2	Progesterone FDA LinkGeneric 01/2017 - 08/2013
2	Estrogens (Estrogen)FDA Link 01/2017 - 08/2013
2	Transcription Factors (Transcription Factor)IBA 11/2016 - 08/2012
2	EWS-FLI fusion proteinIBA 11/2016 - 03/2014
2	Matrix Metalloproteinases (MMPs)IBA 07/2016 - 02/2013
2	Small Interfering RNA (siRNA)IBA 03/2016 - 03/2014
2	CamptothecinIBA 03/2014 - 10/2005
2	Sunitinib (Sutent)FDA Link 10/2013 - 02/2011
2	Phosphotransferases (Kinase)IBA 02/2013 - 02/2011
2	delanzomibIBA 01/2013 - 11/2010
2	Oxaliplatin (Eloxatin)FDA LinkGeneric 07/2012 - 09/2011
2	Fluorouracil (Carac)FDA LinkGeneric 09/2011 - 02/2009

Therapy/Procedure

31	Therapeutics 04/2022 - 08/2007
23	Drug Therapy (Chemotherapy) 01/2022 - 12/2002
5	Aftercare (After-Treatment) 01/2022 - 12/2002
3	Immunotherapy 01/2022 - 01/2020
2	Cytoreduction Surgical Procedures 01/2022 - 07/2019
2	Hyperthermic Intraperitoneal Chemotherapy 07/2019 - 01/2017
2	Salvage Therapy 03/2016 - 03/2005